<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39400381</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>The SARS-unique domain (SUD) of SARS-CoV-2 nsp3 protein inhibits the antiviral immune responses through the NF-κB pathway.</ArticleTitle><Pagination><StartPage>e70007</StartPage><MedlinePgn>e70007</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.70007</ELocationID><Abstract><AbstractText>Nuclear factor κB (NF-κB) plays a crucial role in various cellular processes, including inflammatory and immune responses. Its activation is tightly regulated by the IKK (IκB kinase) complex. Upon severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the virus is initially recognized by the innate immune system and typically activates the NF-κB pathway, leading to a severe inflammatory response. However, the influence of viral proteins upon pro-inflammatory pathway is complicated. Here, we demonstrated that the viral protein nsp3 of SARS-CoV-2 exhibits an unusual function, which attenuated the NF-κB-mediated inflammatory response against SARS-CoV-2 infection in a unique manner. nsp3 interacted with the essential NF-κB modulator NEMO/IKKγ and promoted its polyubiquitylation via the E3 ubiquitin ligase CBL (Cbl Proto-Oncogene). Consequently, polyubiquitylated NEMO undergoes proteasome-dependent degradation, which disrupts NF-κB activation. Moreover, we found that the SARS unique domain (SUD) in nsp3 of SARS-CoV-2 is essential for inducing NEMO degradation, whereas this function is absent in SUD of SARS-CoV. The reduced activation of pro-inflammatory response at an early stage could mask the host immune response and faciliate excessive viral replication. Conversely, this finding may partially explain why SARS-CoV-2 causes a less inflammatory reaction than SARS-CoV, resulting in more mild or moderate COVID-19 cases and greater transmissibility. Given that NEMO is important for NF-κB activation, we propose that inhibiting polyubiquitylation and degradation of NEMO upon SARS-CoV-2 infection is a novel strategy to modulate the host inflammatory response.</AbstractText><CopyrightInformation>© 2024 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Siyi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Shenzhen Key Laboratory for Systems Medicine in Inflammatory Diseases, School of Medicine, Shenzhen Campus of Sun Yat-Sen University, Sun Yat-Sen University, Shenzhen, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Zheng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Institute of Human Virology, Department of Pathogen Biology and Biosecurity, Key Laboratory of Tropical Disease Control of Ministry Education, Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ran</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Human Virology, Department of Pathogen Biology and Biosecurity, Key Laboratory of Tropical Disease Control of Ministry Education, Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Human Virology, Department of Pathogen Biology and Biosecurity, Key Laboratory of Tropical Disease Control of Ministry Education, Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Shuangxin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Research Center, the Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jingliang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Peiming</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Shenzhen Key Laboratory for Systems Medicine in Inflammatory Diseases, School of Medicine, Shenzhen Campus of Sun Yat-Sen University, Sun Yat-Sen University, Shenzhen, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Hanxin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Shenzhen Key Laboratory for Systems Medicine in Inflammatory Diseases, School of Medicine, Shenzhen Campus of Sun Yat-Sen University, Sun Yat-Sen University, Shenzhen, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Kaixin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Shenzhen Key Laboratory for Systems Medicine in Inflammatory Diseases, School of Medicine, Shenzhen Campus of Sun Yat-Sen University, Sun Yat-Sen University, Shenzhen, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yixin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Shenzhen Key Laboratory for Systems Medicine in Inflammatory Diseases, School of Medicine, Shenzhen Campus of Sun Yat-Sen University, Sun Yat-Sen University, Shenzhen, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Siyu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Shenzhen Key Laboratory for Systems Medicine in Inflammatory Diseases, School of Medicine, Shenzhen Campus of Sun Yat-Sen University, Sun Yat-Sen University, Shenzhen, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Human Virology, Department of Pathogen Biology and Biosecurity, Key Laboratory of Tropical Disease Control of Ministry Education, Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Xiancai</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Guangzhou Laboratory, Guangzhou International Bio-Island, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Human Virology, Department of Pathogen Biology and Biosecurity, Key Laboratory of Tropical Disease Control of Ministry Education, Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangzhou Laboratory, Guangzhou International Bio-Island, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Xin</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-2131-2092</Identifier><AffiliationInfo><Affiliation>Institute of Human Virology, Department of Pathogen Biology and Biosecurity, Key Laboratory of Tropical Disease Control of Ministry Education, Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Ting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Shenzhen Key Laboratory for Systems Medicine in Inflammatory Diseases, School of Medicine, Shenzhen Campus of Sun Yat-Sen University, Sun Yat-Sen University, Shenzhen, Guangdong, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>81971918</GrantID><Agency>National Natural Science Foundation of China</Agency><Country /></Grant><Grant><GrantID>2022A1515011038</GrantID><Agency>Guangdong Basic and Applied Basic Research Foundation</Agency><Country /></Grant><Grant><GrantID>ZDSYS20220606100803007</GrantID><Agency>Shenzhen Key Laboratory of Systems Medicine for Inflammatory Diseases</Agency><Country /></Grant><Grant><GrantID>2022YFC0870700</GrantID><Agency>National Key R&amp;D Program of the Department of Science and Technology of China</Agency><Country /></Grant><Grant><GrantID>92169201</GrantID><Agency>Important Key Program of the Natural Science Foundation of China (NSFC)</Agency><Country /></Grant><Grant><GrantID>2022B1111020004</GrantID><Agency>Key R&amp;D Program of the Department of Science and Technology of Guangdong</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C491731">IKBKG protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.10</RegistryNumber><NameOfSubstance UI="D051550">I-kappa B Kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.2</RegistryNumber><NameOfSubstance UI="D000086882">Coronavirus Papain-Like Proteases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000715470">MAS1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000090063">Proto-Oncogene Mas</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.2</RegistryNumber><NameOfSubstance UI="C000706267">papain-like protease, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016328" MajorTopicYN="Y">NF-kappa B</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051550" MajorTopicYN="Y">I-kappa B Kinase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086882" MajorTopicYN="N">Coronavirus Papain-Like Proteases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054875" MajorTopicYN="N">Ubiquitination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090063" MajorTopicYN="N">Proto-Oncogene Mas</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072417" MajorTopicYN="N">Protein Domains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CBL</Keyword><Keyword MajorTopicYN="N">NEMO</Keyword><Keyword MajorTopicYN="N">NF‐κB</Keyword><Keyword MajorTopicYN="N">Nsp3</Keyword><Keyword MajorTopicYN="N">SARS‐CoV‐2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>10</Hour><Minute>47</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39400381</ArticleId><ArticleId IdType="doi">10.1002/jmv.70007</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS‐CoV‐2 and COVID‐19. Nat Rev Microbiol. 2021;19:141‐154.</Citation></Reference><Reference><Citation>Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265‐269.</Citation></Reference><Reference><Citation>Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019‐nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 2020;395:689‐697.</Citation></Reference><Reference><Citation>Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China. N Engl J Med. 2020;382:727‐733.</Citation></Reference><Reference><Citation>Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565‐574.</Citation></Reference><Reference><Citation>Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270‐273.</Citation></Reference><Reference><Citation>Janeway Jr. CA, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197‐216.</Citation></Reference><Reference><Citation>Streicher F, Jouvenet N. Stimulation of innate immunity by host and viral RNAs. Trends Immunol. 2019;40:1134‐1148.</Citation></Reference><Reference><Citation>Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783‐801.</Citation></Reference><Reference><Citation>Blanco‐Melo D, Nilsson‐Payant BE, Liu WC, et al. Imbalanced host response to SARS‐CoV‐2 drives development of COVID‐19. Cell. 2020;181:1036‐1045.e9.</Citation></Reference><Reference><Citation>Gordon DE, Jang GM, Bouhaddou M, et al. A SARS‐CoV‐2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583:459‐468.</Citation></Reference><Reference><Citation>Lowery SA, Sariol A, Perlman S. Innate immune and inflammatory responses to SARS‐CoV‐2: implications for COVID‐19. Cell Host Microbe. 2021;29:1052‐1062.</Citation></Reference><Reference><Citation>Jiang H, Zhang H, Meng Q, et al. SARS‐CoV‐2 Orf9b suppresses type I interferon responses by targeting TOM70. Cell Mol Immunol. 2020;17:998‐1000.</Citation></Reference><Reference><Citation>Shi CS, Qi HY, Boularan C, et al. SARS‐coronavirus open reading frame‐9b suppresses innate immunity by targeting mitochondria and the MAVS/TRAF3/TRAF6 signalosome. J Immunol. 2014;193:3080‐3089.</Citation></Reference><Reference><Citation>Freundt EC, Yu L, Park E, Lenardo MJ, Xu XN. Molecular determinants for subcellular localization of the severe acute respiratory syndrome coronavirus open reading frame 3b protein. J Virol. 2009;83:6631‐6640.</Citation></Reference><Reference><Citation>Konno Y, Kimura I, Uriu K, et al. SARS‐CoV‐2 ORF3b is a potent interferon antagonist whose activity is increased by a naturally occurring elongation variant. Cell Rep. 2020;32:108185.</Citation></Reference><Reference><Citation>Kopecky‐Bromberg SA, Martínez‐Sobrido L, Frieman M, Baric RA, Palese P. Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J Virol. 2007;81:548‐557.</Citation></Reference><Reference><Citation>Miorin L, Kehrer T, Sanchez‐Aparicio MT, et al. SARS‐CoV‐2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling. Proc Natl Acad Sci. 2020;117:28344‐28354.</Citation></Reference><Reference><Citation>Lei X, Dong X, Ma R, et al. Activation and evasion of type I interferon responses by SARS‐CoV‐2. Nat Commun. 2020;11:3810.</Citation></Reference><Reference><Citation>Hackbart M, Deng X, Baker SC. Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors. Proc Natl Acad Sci. 2020;117:8094‐8103.</Citation></Reference><Reference><Citation>Xia H, Cao Z, Xie X, et al. Evasion of Type I interferon by SARS‐CoV‐2. Cell Rep. 2020;33:108234.</Citation></Reference><Reference><Citation>Deng X, Hackbart M, Mettelman RC, et al. Coronavirus nonstructural protein 15 mediates evasion of dsRNA sensors and limits apoptosis in macrophages. Proc Natl Acad Sci. 2017;114:E4251‐E4260.</Citation></Reference><Reference><Citation>Shin D, Mukherjee R, Grewe D, et al. Papain‐like protease regulates SARS‐CoV‐2 viral spread and innate immunity. Nature. 2020;587:657‐662.</Citation></Reference><Reference><Citation>Kamitani W, Narayanan K, Huang C, et al. Severe acute respiratory syndrome coronavirus nsp1 protein suppresses host gene expression by promoting host mRNA degradation. Proc Natl Acad Sci. 2006;103:12885‐12890.</Citation></Reference><Reference><Citation>Thoms M, Buschauer R, Ameismeier M, et al. Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS‐CoV‐2. Science. 2020;369:1249‐1255.</Citation></Reference><Reference><Citation>Lokugamage KG, Narayanan K, Huang C, Makino S. Severe acute respiratory syndrome coronavirus protein nsp1 is a novel eukaryotic translation inhibitor that represses multiple steps of translation initiation. J Virol. 2012;86:13598‐13608.</Citation></Reference><Reference><Citation>Li W, Qiao J, You Q, et al. SARS‐CoV‐2 Nsp5 activates NF‐kappaB pathway by upregulating SUMOylation of MAVS. Front Immunol. 2021;12:750969.</Citation></Reference><Reference><Citation>Wu Y, Ma L, Cai S, et al. RNA‐induced liquid phase separation of SARS‐CoV‐2 nucleocapsid protein facilitates NF‐kappaB hyper‐activation and inflammation. Signal Transduct Target Ther. 2021;6:167.</Citation></Reference><Reference><Citation>Robles JP, Zamora M, Adan‐Castro E, Siqueiros‐Marquez L, Martinez de la Escalera G, Clapp C. The spike protein of SARS‐CoV‐2 induces endothelial inflammation through integrin alpha5beta1 and NF‐kappaB signaling. J Biol Chem. 2022;298:101695.</Citation></Reference><Reference><Citation>Khan S, Shafiei MS, Longoria C, Schoggins JW, Savani RC, Zaki H. SARS‐CoV‐2 spike protein induces inflammation via TLR2‐dependent activation of the NF‐kappaB pathway. eLife. 2021;10:e68563. doi:10.7554/eLife.68563</Citation></Reference><Reference><Citation>Sun SC. The non‐canonical NF‐κB pathway in immunity and inflammation. Nat Rev Immunol. 2017;17:545‐558.</Citation></Reference><Reference><Citation>Hatada EN, Krappmann D, Scheidereit C. NF‐κB and the innate immune response. Curr Opin Immunol. 2000;12:52‐58.</Citation></Reference><Reference><Citation>Dev A, Iyer S, Razani B, Cheng G. NF‐κB and innate immunity. Curr Top Microbiol Immunol. 2011;349:115‐143.</Citation></Reference><Reference><Citation>Karin M. Nuclear factor‐κB in cancer development and progression. Nature. 2006;441:431‐436.</Citation></Reference><Reference><Citation>Karin M, Greten FR. NF‐κB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5:749‐759.</Citation></Reference><Reference><Citation>Li Q, Verma IM. NF‐κB regulation in the immune system. Nat Rev Immunol. 2002;2:725‐734.</Citation></Reference><Reference><Citation>Rothwarf DM, Zandi E, Natoli G, Karin M. IKK‐γ is an essential regulatory subunit of the IκB kinase complex. Nature. 1998;395:297‐300.</Citation></Reference><Reference><Citation>Rudolph D, Yeh WC, Wakeham A, et al. Severe liver degeneration and lack of NF‐κB activation in NEMO/IKKγ‐deficient mice. Genes Dev. 2000;14:854‐862.</Citation></Reference><Reference><Citation>Schmidt‐Supprian M, Bloch W, Courtois G, et al. NEMO/IKKγ‐Deficient mice model incontinentia pigmenti. Mol Cell. 2000;5:981‐992.</Citation></Reference><Reference><Citation>Li Q, Guan X, Wu P, et al. Early transmission dynamics in wuhan, China, of novel Coronavirus‐Infected pneumonia. N Engl J Med. 2020;382:1199‐1207.</Citation></Reference><Reference><Citation>Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395:497‐506.</Citation></Reference><Reference><Citation>Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID‐19 patients. Science. 2020;369:718‐724.</Citation></Reference><Reference><Citation>Wang W, Zhou Z, Xiao X, et al. SARS‐CoV‐2 nsp12 attenuates type I interferon production by inhibiting IRF3 nuclear translocation. Cell Mol Immunol. 2021;18:945‐953.</Citation></Reference><Reference><Citation>Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130:2620‐2629.</Citation></Reference><Reference><Citation>Ritchie AI, Singanayagam A. Immunosuppression for hyperinflammation in COVID‐19: a double‐edged sword? Lancet. 2020;395:1111.</Citation></Reference><Reference><Citation>Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, Hlh Across Speciality Collaboration UK. COVID‐19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033‐1034.</Citation></Reference><Reference><Citation>Tian W, Zhang N, Jin R, et al. Immune suppression in the early stage of COVID‐19 disease. Nat Commun. 2020;11:5859.</Citation></Reference><Reference><Citation>Ghosh S, Karin M. Missing pieces in the NF‐κB puzzle. Cell. 2002;109:S81‐S96.</Citation></Reference><Reference><Citation>Bhoj VG, Chen ZJ. Ubiquitylation in innate and adaptive immunity. Nature. 2009;458:430‐437.</Citation></Reference><Reference><Citation>Wu J, Shi Y, Pan X, et al. SARS‐CoV‐2 ORF9b inhibits RIG‐I‐MAVS antiviral signaling by interrupting K63‐linked ubiquitination of NEMO. Cell Rep. 2021;34:108761.</Citation></Reference><Reference><Citation>Chen DY, Chin CV, Kenney D, et al. Spike and nsp6 are key determinants of SARS‐CoV‐2 Omicron BA.1 attenuation. Nature. 2023;615:143‐150. doi:10.1038/s41586-023-05697-2</Citation></Reference><Reference><Citation>Pan T, Song Z, Wu L, et al. USP49 potently stabilizes APOBEC3G protein by removing ubiquitin and inhibits HIV‐1 replication. eLife. 2019;8:e48318. doi:10.7554/eLife.48318</Citation></Reference><Reference><Citation>Ma X, Zou F, Yu F, et al. Nanoparticle vaccines based on the receptor binding domain (RBD) and heptad repeat (HR) of SARS‐CoV‐2 elicit robust protective immune responses. Immunity. 2020;53:1315‐1330.e9.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>